CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GEN - Genetic Engineering & Biotech News
Original article

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

RadicavaPositive
AI Analysis

Summary

Shionogi acquired Radicava (edaravone), an ALS treatment, from Tanabe Pharma for $2.5 billion as part of a strategic shift toward rare disease drugs.

Importance:7/10
Sentiment:
0.60
M&Arare diseaseALSacquisitionportfolio expansion
Related Companies

Read the original article

Published by GEN - Genetic Engineering & Biotech News on October 6, 2026 7:53 PM

Read Original